# Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

> **NCT01959698** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Roswell Park Cancer Institute** · enrollment: 29 (actual)

## Conditions studied

- CD20 Positive
- Recurrent Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Stage I Diffuse Large B-Cell Lymphoma
- Stage II Diffuse Large B-Cell Lymphoma
- Stage III Diffuse Large B-Cell Lymphoma
- Stage IV Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Carfilzomib
- **DRUG:** Etoposide
- **DRUG:** Ifosfamide
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT01959698
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-04-17
- **Primary completion:** 2020-06-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2026-01-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01959698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01959698, "Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01959698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*